Medical imaging such as CT, MRI and PET scans can be used to make a diagnosis or prognosis, select therapy, monitor responses to therapy and yield pharmacokinetic information about drugs. EORTC’s Imaging research aims to establish and maintain the scientific and clinical value of advanced imaging. We develop specific analytical, review and quality control procedures in the context of EORTC clinical trials.
- IMI QuIC-ConCePT – Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy. The EORTC is coordinating the project. QuIC-ConCePT aims to provide drug developers with imaging biomarkers that can show earlier and more accurately how patients’ tumors respond to drugs in cancer clinical trials. Imaging biomarkers are being tested within series of clinical validation studies including the trial EORTC-1217-IG-LCG “Evaluation of 3′-deoxy-3′-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy” and Trial EORTC-1423-IG-GITCG “Evaluation of diffusion weighted imaging -MRI in patients with resectable liver metastases from colorectal cancer treated with fluoropyrimidine-based chemotherapy as preoperative treatment”.
- IMI2 Tristan – Imaging Biomarkers for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment. The EORTC is coordinating the project. The 5-year project will focus on validation of translational imaging methods as potential imaging biomarkers for the assessment of liver toxicity, lung toxicity and the bio-distribution of biologics. (No website available yet)
- EORTC RP 1106: A three-step study on the feasibility and prognostic value of rCBV in patients with GBM.
(project leader: M. Smits) Three steps project:
- Technical evaluation of acquisition a standardized protocol, centralized data storage, quality assurance.
- Compare quantification to select and test post-processing tools, to standardize methodology for rCBV measurements and to assess inter- and intra- reader variability.
- Prognostic value of rCBV to predict patient outcome.
A publication on repeatability and reproducibility of relative cerebral blood volume measurement in recurrent glioma will be submitted soon.
- EORTC RP 1547 (PICRIB): Platform for imaging in clinical research in Brussels
(project leader: J. Vandemeulebroucke)
PICRIB is a clinical imaging platform that will enable the interoperability of the Brussels university hospitals and facilitate the patient mobility. EORTC is the WP7 lead, and provides guidance regarding standards applicable for imaging used in clinical trial e.g. images acquisition and interpretation, inter-institution quality assurance/ quality control.
Erasmus MC Cancer Institute
Hôpital Européen Georges Pompidou
Lioe-fee de geus-oei
Leiden University Medical Centre
L. Bidaut - Lincoln, GB
Chair of Radiomics subcommittee
University of Lincoln
C. Caramella - Villejuif, FR
Chair of imaging for immunotherapy subcommittee
N. deSouza - Sutton, GB
Chair of Bone- and Oligomets subcommittee
Royal Marsden Hospital Sutton
F. Lecouvet - Brussels, BE
Joint Chair of Bone- and Oligomets subcommittee
Cliniques Universitaires Saint-Luc
N. Aide - Caen, FR
Chair of QA subcommittee
CHU de Caen - Hopital Cote de Nacre
E. Lopci - Milan, IT
CHAIR OF EDUCATION SUBCOMMITTEE
Humanitas Clinical and Research Hospital
Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice
Strategies and Technical Challenges for Imaging Oligometastatic Disease: Recommendations from the EORTC Imaging Group.
Using PET for therapy monitoring in clinical trials: challenges ahead
Imaging biomarker roadmap for cancer studies
Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer e Soft Tissue and Bone Sarcoma Group (EORTC e STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging